Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Total Current Liabilities (2020 - 2025)

Lyell Immunopharma (LYEL) has disclosed Total Current Liabilities for 6 consecutive years, with $49.4 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities fell 8.14% to $49.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $49.4 million through Dec 2025, down 8.14% year-over-year, with the annual reading at $49.4 million for FY2025, 8.14% down from the prior year.
  • Total Current Liabilities hit $49.4 million in Q4 2025 for Lyell Immunopharma, up from $31.9 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $63.7 million in Q2 2021 to a low of $30.8 million in Q1 2023.
  • Historically, Total Current Liabilities has averaged $41.8 million across 5 years, with a median of $37.0 million in 2022.
  • Biggest five-year swings in Total Current Liabilities: crashed 31.62% in 2023 and later soared 55.82% in 2024.
  • Year by year, Total Current Liabilities stood at $46.7 million in 2021, then fell by 20.78% to $37.0 million in 2022, then fell by 6.78% to $34.5 million in 2023, then soared by 55.82% to $53.8 million in 2024, then dropped by 8.14% to $49.4 million in 2025.
  • Business Quant data shows Total Current Liabilities for LYEL at $49.4 million in Q4 2025, $31.9 million in Q3 2025, and $36.9 million in Q2 2025.